Evidence map›Paper›PMID 34283904›Full record

ArticleArchives of endocrinology and metabolism2021

Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.

Guiying Wang, Peng Wu, Yan Qiu, Xin Dong, Yingbin Wang, Yanjun Chi, Fengjuan Zhang, Yinyu Li, Jimin Zhang, Zhengli Huang and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. A narrative review of approved and emerging anti-obesity medications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Review
  11. Review
  12. Effect of Benaglutide on Gut Microbiota and Fecal Metabolites in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Guiying WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Peng WuShanghai Benemae Pharmaceutical Corporation, Shanghai, China.
Yan QiuShanghai Benemae Pharmaceutical Corporation, Shanghai, China.
Xin DongShanghai Benemae Pharmaceutical Corporation, Shanghai, China.
Yingbin WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Yanjun ChiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Fengjuan ZhangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Yinyu LiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Jimin ZhangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Zhengli HuangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Xifeng DuShanghai Benemae Pharmaceutical Corporation, Shanghai, China.
Zhiqiang DuShanghai Benemae Pharmaceutical Corporation, Shanghai, China, duzhiqiang@benemae.com.
Shanxi Datong University · CNHealth First · USHongzhiwei Technology (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers.

methodsThis study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m

resultsAfter three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021).

conclusionBeinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.

Indexed as

Diabetes Mellitus, Type 2AdultBlood GlucoseBody Mass IndexChinaHumansObesityOverweightWeight LossBlood GlucoseGLP-1obesityoverweightT2DM

Identifiers

PMID34283904
PMCPMC10522179
OpenAlexW3185604417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.